AlzeCure Pharma Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Martin Jönsson
Chief executive officer
SEK 2.5m
Total compensation
| CEO salary percentage | 76.6% |
| CEO tenure | 5yrs |
| CEO ownership | 0.5% |
| Management average tenure | 5yrs |
| Board average tenure | 3.7yrs |
Recent management updates
Recent updates
We Think AlzeCure Pharma (STO:ALZCUR) Can Afford To Drive Business Growth
Dec 02
Companies Like AlzeCure Pharma (STO:ALZCUR) Can Afford To Invest In Growth
Jul 20Will AlzeCure Pharma (STO:ALZCUR) Spend Its Cash Wisely?
Oct 12Is AlzeCure Pharma (STO:ALZCUR) In A Good Position To Invest In Growth?
Jan 03Is AlzeCure Pharma (STO:ALZCUR) In A Good Position To Invest In Growth?
Jul 12Is AlzeCure Pharma (STO:ALZCUR) In A Good Position To Invest In Growth?
Mar 28Need To Know: AlzeCure Pharma AB (publ) (STO:ALZCUR) Insiders Have Been Buying Shares
Feb 03We're Not Very Worried About AlzeCure Pharma's (STO:ALZCUR) Cash Burn Rate
Dec 13CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -SEK 36m |
| Jun 30 2024 | n/a | n/a | -SEK 36m |
| Mar 31 2024 | n/a | n/a | -SEK 37m |
| Dec 31 2023 | SEK 2m | SEK 2m | -SEK 37m |
| Sep 30 2023 | n/a | n/a | -SEK 38m |
| Jun 30 2023 | n/a | n/a | -SEK 42m |
| Mar 31 2023 | n/a | n/a | -SEK 53m |
| Dec 31 2022 | SEK 2m | SEK 2m | -SEK 56m |
| Sep 30 2022 | n/a | n/a | -SEK 68m |
| Jun 30 2022 | n/a | n/a | -SEK 73m |
| Mar 31 2022 | n/a | n/a | -SEK 67m |
| Dec 31 2021 | SEK 2m | SEK 2m | -SEK 78m |
| Sep 30 2021 | n/a | n/a | -SEK 73m |
| Jun 30 2021 | n/a | n/a | -SEK 78m |
| Mar 31 2021 | n/a | n/a | -SEK 81m |
| Dec 31 2020 | SEK 2m | SEK 1m | -SEK 71m |
Compensation vs Market: Martin's total compensation ($USD220.72K) is about average for companies of similar size in the Swedish market ($USD232.23K).
Compensation vs Earnings: Martin's compensation has increased whilst the company is unprofitable.
CEO
Martin Jönsson (56 yo)
5yrs
Tenure
SEK 2,475,000
Compensation
Mr. Martin Jönsson is the Chief Executive Officer of AlzeCure Pharma AB (publ) since January 8, 2020. Mr. Jönsson served in a senior position at Ferring Pharmaceuticals in the US, he was business area dire...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 5yrs | SEK 2.48m | 0.46% SEK 532.3k | |
| Chief Financial Officer | 8yrs | no data | 0.14% SEK 159.3k | |
| Chief Scientific Officer | 5yrs | SEK 1.28m | 0.99% SEK 1.1m | |
| Chief Medical Officer & Head of Development | 3.8yrs | no data | 0.084% SEK 96.4k | |
| Head of Research & Discovery | 8yrs | no data | 1.03% SEK 1.2m |
5.0yrs
Average Tenure
57yo
Average Age
Experienced Management: ALZCUR's management team is seasoned and experienced (5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 8yrs | SEK 229.00k | 1.7% SEK 2.0m | |
| Director | less than a year | no data | no data | |
| Independent Director | 8yrs | SEK 115.00k | 0.056% SEK 64.6k | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Independent Director | 1.7yrs | SEK 73.00k | 0.028% SEK 32.5k | |
| Scientific Advisor | no data | no data | no data | |
| Independent Director | 3.7yrs | SEK 115.00k | 0.0028% SEK 3.2k |
3.7yrs
Average Tenure
70yo
Average Age
Experienced Board: ALZCUR's board of directors are considered experienced (3.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/12 13:52 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
AlzeCure Pharma AB (publ) is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jonas Peciulis | Edison Investment Research |
| Fredrik Thor | Redeye |
| Felicia Rittemar | Vator Securities AB |